GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

People with kidney disease may be at higher risk of anxiety and depression. But taking care of your mental health can have a positive effect on your outlook with kidney disease. Chronic kidney ...

The FLOW phase 3b trial showed significant reductions ... need for patients with both type 2 diabetes (T2D) and chronic kidney disease (CKD), addressing their cardiovascular (CV) and kidney ...

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

Lithium is associated with an increased risk for thyroid dysfunction and chronic kidney disease (CKD) in patients with ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with ...

“These patients often have concomitant cardiovascular disease, they have chronic kidney disease ... reviewing data from Ozempic’s phase 3b FLOW kidney outcomes trial, which found the Novo ...

Efficacy was established based on the time to first occurrence of a primary composite endpoint event, defined as onset of persistent 50% or greater reduction in eGFR according to the Chronic Kidney ...

Novo Nordisk’s Ozempic (semaglutide) has been approved by the US Food and Drug Administration (FDA) to reduce the risk of kidney disease worsening, kidney failure and cardiovascular disease (CVD) ...